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Abstract
Introduction: Infections are still the most common complications of cerebral shunt procedures. Even though fungal etiologies are
considered to be rare, they are associated with significant morbidity and mortality. Due to their uncommonness, diagnostic
procedures and optimal therapy are poorly defined. We report a case of Candida tropicalis infection of ventriculo-peritoneal
cerebrospinal fluid (CSF) shunt in a 49-year-old immune competent male treated with voriconazole (VOR).
Methods: Microbiological and CSF markers (1,3-b-D-glucan-BDG) of fungal infection, biofilm production capacity, sensitivity of
serial isolates of the pathogen, and the concentration of the antifungal drug have been monitored and related to the clinical course of
this infection.
Results: Despite appropriate treatment with VOR, in terms of adequate achieved CSF drug concentrations and initial effective
therapeutic response, loss of VOR susceptibility of the C tropicalis and treatment failure were observed.
Conclusion: Biofilm production of the C. tropicalis isolate might have had a significant role in treatment failure. Of interest, clinical
and microbiological unfavorable outcome was anticipated by persistence of BDG in CSF. Rising titers of this marker were associated
with relapse of fungal infection.
Abbreviations: BFI = biofilm index, CNS = central nervous system, CSF = cerebrospinal fluid, DG = (1,3)-b-D-Glucan, EVD =
external ventricular drainage, FLU = Fluconazole, HPLC = high-performance liquid chromatography, IDSA = Infectious Diseases
Society of America, LAMB = Amphotericin B, MIC = minimal inhibitory concentration, TDM = therapeutic drug monitoring, VOR =
Voriconazole, VP = ventriculo-peritoneal.
Keywords: 1,3-b-D-glucan, biofilm, Candida tropicalis, case report, cerebrospinal fluid shunt, meningitis, voriconazole1. Introduction
Candida species are an uncommon cause of central nervous
system (CNS) infections.[1] Until now, few cases of Candida
tropicalis infections of CNS have been reported in the medical
literature.[2,3] Therefore, risk factors, prognosis, diagnosticEditor: Liang Jin.
On behalf of all authors, the corresponding author states that there is no conflict
of interest.
a Department of Public Health and Infectious Diseases. University of Rome
“Sapienza”, Azienda Policlinico Umberto I, Rome, bDepartment of Health
Sciences (DSS), Section of Clinical Pharmacology and Oncology, Università degli
Studi, Florence, Italy.
∗
Correspondence: Mario Venditti, Department of Public Health and Infectious
Diseases, University of Rome “Sapienza”, Azienda Policlinico Umberto I, Viale del
Policlinico 155, 00161 Rome, Italy (e-mail: mario.venditti@uniroma1.it).
Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All
rights reserved.
This is an open access article distributed under the Creative Commons
Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Medicine (2016) 95:31(e4474)
Received: 10 April 2016 / Received in final form: 9 July 2016 / Accepted: 11 July
2016
http://dx.doi.org/10.1097/MD.0000000000004474
1procedures, and optimal therapy are poorly defined. Despite
appropriate therapy, the referred mortality of patients affected by
C tropicalis meningitis approached 30%.[1,2] We describe a case
of an infection of the cerebrospinal fluid (CSF) shunt device in a
middle-aged patient sustained byC tropicalis. Peculiarities of this
report of such a rare infection are that measurement of (1,3)-b-D-
Glucan (BDG) in the CSF, biofilm production capacity and
modifications of the azole susceptibility of serial isolates of the
pathogen, as well as antifungal drugs CSF concentration have
been monitored and related to the clinical outcome.2. Case report
A 49-year-old immune-competent male was admitted to the
Neurosurgical IntensiveCare for fever (up to38°C) associatedwith
ideomotor slowdown, severe confusional state, and meningism.
Two months prior hospitalization, the patient underwent surgical
removal of a pontocerebellar acoustic neuroma with placement of
a ventriculo-peritoneal (VP) shunt and received an successful
10-day Fluconazole (FLU) treatment course for a catheter-related
C tropicalis urinary tract infection. CSF analysis, performed at the
admission, revealed glucose concentration of 34.2mg/dL, protein
level of 332mg/dL, and leukocytes cell count of 471cells/mL (75%
polymorphonucleocytes). No signs of persistent Candida urinary
Ceccarelli et al. Medicine (2016) 95:31 Medicinetract infection were found in serial urine analysis and cultures
performed during this second hospitalization. Fungal meningitis
was diagnosed on the basis of C tropicalis isolation from the CSF
culture. The same pathogen was also cultured from the removed
VP shunt, while blood cultures were negative. Intravenous
voriconazole (VOR) was started (loading dose 6mg/Kg/q12 forFigure 1. Clinical course, microbiological and laboratory monitoring of meningitis
WBC=cerebrospinal fluid white blood cells, CSF=cerebrospinal fluid, EDV=exte
(conc)=voriconazole concentrations in cerebrospinal fluid).
22 doses, then 4mg/Kg/q12) and an external ventricular drainage
(EVD) was inserted. The clinical course and the main laboratory
findings, expressed in function of time, are shown in Fig. 1.
On day 13, 22, and 29 of VOR treatment, C tropicalis was
still cultured from CSF and consequently EVD was changed.
On the day 31 of VOR treatment, CSF cell count and glucosecaused by C tropicalis. CSF BDG=cerebrospinal fluid (1,3)-b-D-Glucan, CSF
rnal ventricular drainage, MICs=minimal inhibitory concentrations, VOR BDG
Ceccarelli et al. Medicine (2016) 95:31 www.md-journal.comconcentration achieved normal values and CSF culture yielded no
microbial growth. With apparent C tropicalis microbial
eradication from CSF, a clinical improvement of patient’s
condition in terms of Glascow Coma Score (Fig. 1) has been
observed with initial impressive reduction of CSF BDG.
C tropicaliswas isolated again from the CSF culture on the day
48 of therapy concurrently with new clinical-neurological
deterioration. Increased CSF BDG levels proceeded new isolation
of the offending pathogen from CSF. No increase in serum BDG
has been detected in day 16, 34, 45 of VOR treatment (Fig. 1).
VOR was replaced by liposomal Amphotericin B (LAMB)
(3mg/kg/daily) along with FLU (loading dose 800mg, then
400mg/daily) and EVD was changed again. On the day 66 of
antifungal therapy, the patient died for a concurrent bacterial
sepsis, showing no further significant clinical improvement of
his meningitis after the replacement of VOR by LAMB along
with FLU. CSF cultures remained positive for C tropicalis. Given
that interventions and all investigations described in this case
report were performed as part of the standard health care whose
informed consent was obtained, no ethical approval was either
sought or obliged.3. Microbiological and laboratory studies
3.1. C tropicalis susceptibility testing
The antifungal susceptibility of C tropicalis in CSF samples was
tested by means of the minimal inhibitory concentrations (MICs)
measurement (Sensititre Yeast One 10; Trek Diagnostic Systems
Thermo Fisher Scientific, Rodano (MI), Italy), according to CLSI
M27A3 guidelines.[4] The susceptibility of the C tropicalis
isolates was monitored and the changes recorded over the time
(Table 1). A gradual rise (up to 2 log2 dilution factor) of theVOR
MICs was observed in serial CSF C tropicalis isolates.3.2. C tropicalis biofilm production
Biofilm production by C tropicalis strains was measured through
XTT-reduction dehydrogenase assay and expressed as the ratio
of the mean sample absorbance performed in triplicate experi-
ments, over the 50% mean absorbance of a reference C. albicans
strain (SA40, kind gift of F. De Bernardis, National Health
Institute), in terms of biofilm index (BFI).[5,6] Clinical isolates
with BFI ≥0.5 were considered biofilm-producing strains. The
aim of this experiment was to determine eventual time-related
changes in biofilm-forming ability of strains of C tropicalis
isolated from the CSF samples. All the isolates of C tropicalis
were biofilm producers. The BFI fell from 2.1 to 1.1, with a 52%
reduction at day 40. The recurrence of the isolation ofC tropicalisTable 1
Changes of susceptibility of C tropicalis isolates tested were reporte
Candida tropicalis (MICs) Day 1
Fluconazole 1
Voriconazole 0.06
Itraconazole 0.25
Amphotericin B 0.5
Anidulafungin 0.015
Caspofungin 0.008
Micafungin 0.015
5-Fluorocytosine 0.06
MICs= minimal inhibitory concentrations.
3on the day 48was accompanied by a rise in the BFI (1.6 and 1.4 at
days 48 and 52, respectively).3.3. CSF (1,3)-b-D-glucan measurement
CSF BDGmeasurement was performed by a method based upon a
modification of the Limulus amebocyte lysate pathway, using a
commercially available diagnostic kit (Fungitell; Cape Cod Inc.,
East Falmouth, MA, USA), according to the manufacturer
instructions. Glucan-free dilution tubes and pipette tips were
used, and all assays were performed in a biosafety cabinet that had
not been used to manipulate fungal cultures. Individuals perform-
ing the assay were blinded to all diagnostic and clinical
information. This analysis was performed posthumously on CSF
samples stored in the biobank. Our results showed a progressive
decrease in the levels ofCSFBDG (from5230 to1233pg/mL), even
though the values were constantly high and the negativity of the
marker was never reached. Of note was a new gradual rise in the
BDG in the CSF samples some days before the new isolation of
C tropicalis (Fig. 1).
3.4. Voriconazole CSF concentrations
VORplasma concentrationwas determined by high-performance
liquid chromatography (HPLC), using Perkin Elmer chromato-
graph (Series 200, Beaconsfield, Perkin Elmer, USA) with
wavelength ultraviolet (UV) detector set at 255nm. An aliquot
(0.5mL) was pipetted into a 2mL polypropylene tube (Sarstedt,
Leicester, UK) and acetonitrile (1.0mL) added. The mixture was
vortex mixed briefly and after standing for 10minutes at room
temperature the mixture was centrifuged at 1200g for 10
minutes. Then, the supernatant was transferred in polypropylene
autosampler vial and 0.180mL injected into the HPLC system.
This assay was linear (r=0.9997) over the concentration of 0.1 to
50mg/L. Validation data for accuracy and precision were
coefficient of variation between 2.4% and 7.3%; intra-day
accuracy was in the range of 95% to 106.5 %.[7]
A median CSF VOR concentration of 2mg/L (range 0.27–3.82
mg/L) was registered, while the mean blood level of VOR was
2.48mg/L (range 1.91–3.05mg/L). The CSF/plasma VOR
concentration ratio was 0.8. The CSF VOR concentrations
observed were always higher than the coevalMIC ofC tropicalis.
4. Discussion
The Italian Consensus for invasive candidiasis management
(ITALIC) has suggested that VOR should be used as a first-line
treatment for CNS Candida infections.[8] The rationale for the
use of this drug in this setting is linked to its ability to reach highd in function of the time.
Day 28 Day 48
1 1
0.12 0.25
0.25 0.12
0.5 0.5
0.015 0.015
0.03 0.03
0.015 0.03
0.06 0.06
[9–11]
Ceccarelli et al. Medicine (2016) 95:31 Medicineconcentrations in the CSF. Lutsar et al reported that in
patients treated with VOR for CNS fungal infections, the median
CSF/plasma ratio was 0.46 (range 0.22–1.0).[9] Wiederhold
et al,[10] testing 173 CSF samples, confirmed a similar result
(CSF/plasma ratio 0.52) and described that the median
quantifiable CSF level of VOR was 2.47mg/L (range 0–15.3
mg/L) with CSF concentrations more heavily distributed toward
the lower end of the range. However, the CSF concentration and
the ratio may vary depending on the serum drug concentrations
and is influenced by several variables such as liver disease, age,
genetic polymorphism of the cytochrome CYP2C19, and
comedications.[11] These variables may lead to large inter- and
intra-patient differences in VOR pharmacokinetic, perhaps
sometimes associated with a decreased efficacy. Therefore,
therapeutic drug monitoring (TDM) is required to improve the
efficacy and the safety of VOR therapy in patients with invasive
mycoses.
VOR was used in our case and the drug achieved plasma
and CSF levels that should have provided a clinical efficacy
(CSF/plasma concentration ratio of 0.8). Furthermore, the MICs
of C tropicalis isolates, ranging from 0.06 to 0.25mg/L, were
always below the resistance breakpoint that is >0.5mg/l,
according to the CLSI interpretation.[12] However, a progressive
increase of the MIC values was observed during the course of
VOR treatment and a value of 0.25mg/L was observed on day 48
of VOR therapy. To date, according to new CLSI VOR clinical
breakpoints for C tropicalis (available only after the occurrence
of the described case), MICs values for VOR of 0.25 to 0.5mg/L
should be interpreted as intermediate sensitivity.[12] Of interest, a
recent Italian study reported that 99% of the isolates of C
tropicalis tested were highly susceptible to VOR (0.008mg/L
MICs 0.25mg/L; MIC50 0.03mg/L; and MIC90 0.06mg/L)
with only 1 out of 102 isolates showing dose-dependent
susceptibility.[13] These data were confirmed by the results of a
large multicenter study conducted in Europe and North and
South America where only 2.2% and 3.5% of 3127 C tropicalis
isolates showed MICs for VOR of 0.25 and ≥0.5mg/L,
respectively.[14] As a matter of fact, in our case, we cannot
exclude that the above-mentioned loss in susceptibility to VOR
might have affected the efficacy of therapy.
Following VOR treatment failure, LAMB as well as FLU
therapy was attempted on the basis of previous apparently
favorable in vivo and in vitro observations of this antifungal
agents combination.[15,16] However, the efficacy of this salvage
therapy could not be fully evaluated, as the patient finally died for
bacterial superinfection.
Further insights might be gained by the observation of biofilm
production by all consecutive fungal isolates. Indeed, the ability
ofC tropicalis to form biofilm on devices is considered a potential
virulence factor and might have represented another limitation
for therapy with VOR (or LAMB) in our case.[17,18] Such a
phenomenon might be strongly implicated in the final VOR
treatment failure despite susceptibility of fungal isolates and
prompt removal and substitution of EVDs.
Of interest, as shown in Fig. 1, a progressive reduction of BFI
has been observed in serial isolates during antifungal therapy. To
this end, recent studies showed that VOR fails to eradicate
Candida spp. in mature biofilm, but seems to display in vitro
efficacy in the reduction of biofilm formation.[19–21] Of course,
knowledge of the clinical significance of these observations
requires for further investigations.
The therapeutic efficacy of VOR was initially assumed by the
progressive restoration of the normal physical-chemical and4microbiological CSF parameters. These findings were also
indirectly confirmed by the gradual decline of CSF BDG observed
until a few days before the recurrence of positive CSF culture
under VOR therapy. Erythrocyte sedimentation rate (ESR), C
reactive protein (CRP), and BDG might be used for monitoring
efficacy of antifungal therapy. Nevertheless, ESR and CRP are
nonspecific inflammatory markers and can be affected by
concomitant conditions such as concurrent bacterial infections
that compromise their usefulness in monitoring the fungal disease
in critically ill patients, as it occurred in our patients.[22]
Therefore, due to these possible bias, serum and/or BDG seem to
be a suitable marker in this setting.[23]
Recent studies, performed in animal models and on human
beings, proposedCSF BDG as a marker for the detection of fungal
infections in the CNS and for clinical therapymonitoring.[24–28] In
our case, duringVOR treatment, the retrospective analysis in serial
samples of CSF demonstrated persistence of BDG, even when
cultures yielded no microbial growth, albeit with a progressive
reduction of titers. On the basis of these observations, persistence
of BDG in the CSF might suggest the need for maintaining the
antifungal treatment despite negative cultures. On the contrary,
clearance of this marker might suggest the optimal timing to
repositionaVPshunt.Not less important, a sudden increaseofCSF
BDGvalues during antifungal therapy, as that observed in our case
before the C tropicalis recurrence, might represent a warning sign
for the treatment failure.
On the contrary, serum BDG levels do not seem to be
concordant with CSF BDG levels: in fact in our case, BDG values
were significantly higher in CSF than in blood. As previously
suggested, this gap could suggest isolated CNS infection without
significant spillover into venous blood or that BDG may be more
rapidly cleared in blood than in CSF.[26] According with the
results of the fungal meningitis rabbit model proposed by
Petraitiene et al,[29] plasmatic levels of b-glucan lower than CSF
levels hint a compartmentalization of this polymeric carbohy-
drate, with higher concentrations within the CNS not readily
crossing the blood–brain barrier. Taken together, these data
could indicate that serum BDG values may not be helpful in
determining invasion of the CNS by a fungal pathogen.
Finally, despite the data supporting the efficacy of VOR in CNS
fungal infections, use of this azole as first-line therapy in CSF
Candida infections, as proposed by ITALIC,[8] is not shared by
the most recent guidelines for the “Management of Candidiasis,”
updated by the Infectious Diseases Society of America (IDSA) in
2016.[12] In these recommendations, VOR is not cited as a
possible choice in the treatment of CSN Candida infections,
although it is recognized that it can achieve significant CSF
concentration, potentially active against susceptible isolates, and
it has been shown to be efficacious in small case series.[8–10,12]
Wide variability in serum levels, need of the TDM, common
drug–drug interactions with potential toxicity might have
discouraged the use of VOR in these Guidelines.5. Conclusions
We described a rare case of C tropicalis meningitis wherein
appropriate treatment with VOR, in terms of adequate achieved
CSF drug concentrations, was associated with loss of VOR
susceptibility of the offending pathogen and treatment failure. Of
interest, clinical and microbiological unfavorable outcome was
anticipated by persistence of BDG in CSF. Eventually, rising titers
of this marker were associated with clinical and microbiological
relapse of fungal infection. Biofilm production of the C tropicalis
[15] Rex JH, Pappas PG, Karchmer AW, et al. A randomized and
Ceccarelli et al. Medicine (2016) 95:31 www.md-journal.comisolate might have had a significant role in treatment failure. The
importanceof all thesedata shouldbe confirmedby further studies.
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